title: Mesoporous iron-carboxylate metal-organic frameworks synthesized by the double-template method as a nanocarrier platform for intratumoral drug delivery.
abstract: Metal-organic frameworks as a powerful platform for drug delivery have attracted significant attention in recent years. In this study, mesoporous iron-metal-organic framework nanoparticles (mesoMOFs) were synthesized via the double-template method. Cetyltrimethylammonium bromide (CTAB) and citric acid (CA) were chosen as the double-template agent. The mesoMOFs were characterized by EDX, elemental analysis, TG, BET, SEM, TEM, and DLS. The anticancer drug doxorubicin hydrochloride (DOX) was encapsulated in the mesoMOFs, and the DOX loading content was up to 55 wt%. The mesoMOFs are non-toxic to both 4T1 breast cancer cells and 3T3 fibroblasts. The DOX-loaded mesoMOFs exhibit a better anti-tumor effect than free doxorubicin in vitro. The in vivo anticancer activities of the DOX-loaded mesoMOFs were investigated in 4T1 breast cancer-bearing mice. The intratumoral injection of DOX-loaded mesoMOFs revealed that the mesoMOFs could significantly reduce the systemic toxicity of DOX, sustainably release DOX, and maintain an effective DOX concentration for chemotherapy. The DOX-loaded mesoMOFs exhibit excellent therapeutic efficacy and low side effects in local chemotherapy.
authors.affiliation: College of Chemical Engineering, Sichuan University, Chengdu 610065, China. lisai@scu.edu.cn.
authors.forename: Zhengfei
authors.initials: Z
authors.lastname: Wu
authors.forename: Na
authors.initials: N
authors.lastname: Hao
authors.forename: Hai
authors.initials: H
authors.lastname: Zhang
authors.forename: Zhaoyuan
authors.initials: Z
authors.lastname: Guo
authors.forename: Rong
authors.initials: R
authors.lastname: Liu
authors.forename: Bin
authors.initials: B
authors.lastname: He
authors.forename: Sai
authors.initials: S
authors.lastname: Li
mesh_terms: D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage* / Q000627:therapeutic use; D045744:Cell Line, Tumor; D004317:Doxorubicin / Q000008:administration & dosage* / Q000627:therapeutic use; D004337:Drug Carriers / Q000737:chemistry*; D016503:Drug Delivery Systems / Q000379:methods; D005260:Female; D007501:Iron / Q000737:chemistry*; D008297:Male; D015674:Mammary Neoplasms, Animal / Q000188:drug therapy* / Q000473:pathology; D000073396:Metal-Organic Frameworks / Q000737:chemistry*; D051379:Mice; D041681:NIH 3T3 Cells
chemical_list: D000903:Antibiotics, Antineoplastic; D004337:Drug Carriers; D000073396:Metal-Organic Frameworks; D004317:Doxorubicin; D007501:Iron